Combined treatment with DPP4 and SGLT2 inhibitors has been proposed as an effective treatment option for T2DM given their complementary mechanisms of action and low risk of hypoglycemia or weight gain [10, 11, 15]. This evidence concerns the gene DPP4 and Hypoglycemia.